Related Experiment Video

Updated: Sep 29, 2026

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication

Kathrin Bernt1, Min Liang, Xun Ye

  • 1Division of Medical Genetics, University of Washington, Seattle, Washington 98195, USA.

Journal of Virology
|October 9, 2002
PubMed

Insights

New adenovirus vectors (Ad.IR-E1A) replicate specifically in tumor cells, enhancing transgene expression and viral spread for targeted cancer therapy. These vectors show significant antitumor efficacy in preclinical models.

Area of Science:

  • Oncolytic virotherapy
  • Gene therapy vectors
  • Adenovirus vector engineering

Background:

  • Adenovirus vectors with E1A and E1B gene deletions exhibit tumor-selective replication.
  • This selective replication is observed in various human tumor cell lines but not in primary human or mouse liver cells.
  • Homologous recombination within inverted repeats can create replication-dependent transgene expression systems.

Purpose of the Study:

  • To develop an adenovirus vector system (Ad.IR) for tumor-selective transgene expression and replication.
  • To engineer Ad.IR vectors expressing wild-type E1A (Ad.IR-E1A) to enhance viral replication and spread in tumors.
  • To evaluate the tumor-specific expression, replication, spread, and antitumor efficacy of Ad.IR-E1A vectors.

Main Methods:

  • Development of Ad.IR vectors utilizing homologous recombination for precise genomic rearrangements.
  • Introduction of wild-type E1A gene into Ad.IR vectors to create Ad.IR-E1A.
  • In vitro studies assessing DNA replication and cytotoxicity in tumor versus nontransformed cells.
  • In vivo studies involving systemic administration of Ad.IR-E1A into animal models with liver metastases and subcutaneous tumors.

Main Results:

  • Ad.IR-E1A vectors demonstrated efficient and specific E1A-enhanced replication and transgene expression in tumor cells, not in normal human cells.
  • Systemic administration resulted in exclusive transgene expression within liver metastases.
  • Increased number of transgene-expressing tumor cells over time indicated viral replication and spread.
  • Ad.IR-E1A vectors exhibited significant antitumor efficacy in both subcutaneous and metastatic cancer models.

Conclusions:

  • Ad.IR-E1A vectors provide a novel platform for tumor-specific transgene expression and replication.
  • These vectors facilitate efficient viral spread within liver metastases following systemic application.
  • The combination of tumor-selective expression, replication, and spread offers a promising strategy for oncolytic virotherapy.

Related Concept Videos

Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Recombinant DNA Technology01:34

Recombinant DNA Technology

Scientists create recombinant DNA by combining DNA from different sources—often, other species—in the laboratory. DNA cloning allows researchers to study specific genes by inserting them into easily manipulated cells, such as bacteria. Organisms that contain recombinant DNA are known as genetically modified organisms (GMOs). Recombinant DNA technology produces organisms with new genes that can benefit science, medicine, and agriculture.How Do Scientists Create Recombinant DNA?Creation of...
Viral Recombination00:57

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.